Marty Makary departs FDA after clashes over fruit-flavored vapes with Trump | Trump administration
Marty Makary resigned from his post as commissioner of the U.S. Food and Drug Administration (FDA) on Tuesday, Donald Trump confirmed Tuesday, completing a 13-month tenure at the regulatory agency that has frequently drawn the ire of the White House, Congress, industry and the public.
It was reported that Kyle Diamantas, who previously worked as a senior food official at the institution that determines the strategic direction and operations of food policy in the United States, will replace Makary. PolicyThe first to report the resignation and replacement of Makary.
Embers signed on a plan to fire Makary earlier this month after the president scolded Because the FDA chief has not approved fruit-flavored e-cigarettes, according to the Wall Street Journal.
When asked about Makary on Friday, Trump said, “He looks good.” When asked if he would fire Makary, Trump said: “I’ve read about it, but I don’t know anything.”
Trump on Tuesday said Reporters at the White House said Makary was a “great guy” but “had some difficulties.”
“He’s a great doctor and he’s had some struggles, but he’s going to move on and he’s going to be successful. Everybody wants this job,” Trump added.
Makary in the beginning override Agency scientists will pause approval of the first fruity e-cigarettes on the market before the FDA announced approval would move forward last week.
Electronic cigarettes weren’t the first stance Makary took as FDA chief. He also clashed with lawmakers on Capitol Hill over drug regulatory decisions by conservative members of Congress and the review of mifepristone, an abortion drug. blamed him from walking slowly. There is ample scientific evidence regarding the safety and importance of mifepristone.
The FDA has also halted the publication of studies on the safety of vaccines against shingles and Covid, showing a “pattern” of “not allowing the dissemination of information that might support the overall safety of the vaccines,” said Janet Woodcock, the FDA’s former acting commissioner. Other controversial decisions regarding vaccines included refusing to evaluate Moderna’s new flu vaccine; this decision was soon reversed after public outcry.
The Trump administration has avoided discussing unwelcome changes to routine vaccine recommendations ahead of the midterm elections.
“Vaccines have really captured their attention,” said Peter Lurie, executive director of the Center for Science in the Public Interest and a former commissioner of the FDA. “They understand that they have gone too far for the American people on the vaccine issue.”
Darin LaHood, a Republican congressman from Illinois, told a House ways and means committee budget hearing last month that the FDA’s “mismanagement and incompetent drug reviews” are “chilling investments in life-saving, innovative treatments.” Republican senator Ron Johnson of Wisconsin said in March: to research FDA for rejecting rare disease treatments.
Lurie said the wave of layoffs and appointments of inexperienced officials created “massive upheaval that has been an ongoing feature of daily work at the FDA since the new administration began.” “It’s just endless chaos.”
There are also concerns about renewed guidance for clinical trials, the commissioner’s new priority review documents and “data-neutral” regulatory decisions.
Some key positions in the Trump administration remain vacant. Neither Nicole Saphier, Trump’s third pick to be US surgeon general, nor Erica Schwartz, who will become the fifth director of the US Centers for Disease Control and Prevention (CDC) last year, have yet to go through the confirmation process before the Senate. Jay Bhattacharya, director of the National Institutes of Health, is temporarily leading the CDC.
